{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:07:24Z","timestamp":1761102444275,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s10741-020-10022-4","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T22:02:48Z","timestamp":1598997768000},"page":"381-389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Renin-angiotensin-system inhibition in the context of corona virus disease-19: experimental evidence, observational studies, and clinical implications"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6433-4016","authenticated-orcid":false,"given":"Filippos","family":"Triposkiadis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall C.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Xanthopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harisios","family":"Boudoulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"issue":"7","key":"10022_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016509","volume":"9","author":"R Sommerstein","year":"2020","unstructured":"Sommerstein R, Kochen MM, Messerli FH, Grani C (2020) Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc 9(7):e016509. https:\/\/doi.org\/10.1161\/JAHA.120.016509","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10022_CR2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","volume":"98","author":"RAS Santos","year":"2018","unstructured":"Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ (2018) The ACE2\/angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7). Physiol Rev 98(1):505\u2013553. https:\/\/doi.org\/10.1152\/physrev.00023.2016","journal-title":"Physiol Rev"},{"issue":"1","key":"10022_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1161\/HYPERTENSIONAHA.119.14071","volume":"75","author":"P Serfozo","year":"2020","unstructured":"Serfozo P, Wysocki J, Gulua G, Schulze A, Ye M, Liu P, Jin J, Bader M, Myohanen T, Garcia-Horsman JA, Batlle D (2020) Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent. Hypertension 75(1):173\u2013182. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14071","journal-title":"Hypertension"},{"issue":"3","key":"10022_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1165\/rcmb.2015-0108OC","volume":"54","author":"T Szul","year":"2016","unstructured":"Szul T, Bratcher PE, Fraser KB, Kong M, Tirouvanziam R, Ingersoll S, Sztul E, Rangarajan S, Blalock JE, Xu X, Gaggar A (2016) Toll-like receptor 4 engagement mediates prolyl endopeptidase release from airway epithelia via exosomes. Am J Respir Cell Mol Biol 54(3):359\u2013369. https:\/\/doi.org\/10.1165\/rcmb.2015-0108OC","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10022_CR5","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/HYPERTENSIONAHA.118.10918","volume":"72","author":"M Bader","year":"2018","unstructured":"Bader M, Alenina N, Young D, Santos RAS, Touyz RM (2018) The meaning of Mas. Hypertension 72(5):1072\u20131075. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.10918","journal-title":"Hypertension"},{"issue":"23","key":"10022_CR6","doi-asserted-by":"publisher","first-page":"14614","DOI":"10.1128\/JVI.79.23.14614-14621.2005","volume":"79","author":"HP Jia","year":"2005","unstructured":"Jia HP, Look DC, Shi L, Hickey M, Pewe L, Netland J, Farzan M, Wohlford-Lenane C, Perlman S, McCray PB Jr (2005) ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol 79(23):14614\u201314621. https:\/\/doi.org\/10.1128\/JVI.79.23.14614-14621.2005","journal-title":"J Virol"},{"issue":"2","key":"10022_CR7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1128\/JVI.02202-13","volume":"88","author":"A Heurich","year":"2014","unstructured":"Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S (2014) TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol 88(2):1293\u20131307. https:\/\/doi.org\/10.1128\/JVI.02202-13","journal-title":"J Virol"},{"key":"10022_CR8","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1161\/CIRCRESAHA.120.317015","volume":"126","author":"M Gheblawi","year":"2020","unstructured":"Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Raizada MK, Grant MB, Oudit GY (2020) Angiotensin converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system. Circ Res 126:1456\u20131474. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317015","journal-title":"Circ Res"},{"issue":"6","key":"10022_CR9","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1161\/HYPERTENSIONAHA.114.03871","volume":"64","author":"V Shenoy","year":"2014","unstructured":"Shenoy V, Kwon KC, Rathinasabapathy A, Lin S, Jin G, Song C, Shil P, Nair A, Qi Y, Li Q, Francis J, Katovich MJ, Daniell H, Raizada MK (2014) Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. Hypertension 64(6):1248\u20131259. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.03871","journal-title":"Hypertension"},{"issue":"1\u20133","key":"10022_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejphar.2013.04.017","volume":"713","author":"K Rigatto","year":"2013","unstructured":"Rigatto K, Casali KR, Shenoy V, Katovich MJ, Raizada MK (2013) Diminazene aceturate improves autonomic modulation in pulmonary hypertension. Eur J Pharmacol 713(1\u20133):89\u201393. https:\/\/doi.org\/10.1016\/j.ejphar.2013.04.017","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10022_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00109-012-0859-2","volume":"90","author":"GJ Rey-Parra","year":"2012","unstructured":"Rey-Parra GJ, Vadivel A, Coltan L, Hall A, Eaton F, Schuster M, Loibner H, Penninger JM, Kassiri Z, Oudit GY, Thebaud B (2012) Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. J Mol Med (Berl) 90(6):637\u2013647. https:\/\/doi.org\/10.1007\/s00109-012-0859-2","journal-title":"J Mol Med (Berl)"},{"issue":"2","key":"10022_CR12","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/CCM.0b013e3181c03009","volume":"38","author":"B Treml","year":"2010","unstructured":"Treml B, Neu N, Kleinsasser A, Gritsch C, Finsterwalder T, Geiger R, Schuster M, Janzek E, Loibner H, Penninger J, Loeckinger A (2010) Recombinant angiotensin-converting enzyme 2 improves pulmonary blood flow and oxygenation in lipopolysaccharide-induced lung injury in piglets. Crit Care Med 38(2):596\u2013601. https:\/\/doi.org\/10.1097\/CCM.0b013e3181c03009","journal-title":"Crit Care Med"},{"issue":"3","key":"10022_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/path.2067","volume":"210","author":"L He","year":"2006","unstructured":"He L, Ding Y, Zhang Q, Che X, He Y, Shen H, Wang H, Li Z, Zhao L, Geng J, Deng Y, Yang L, Li J, Cai J, Qiu L, Wen K, Xu X, Jiang S (2006) Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol 210(3):288\u2013297. https:\/\/doi.org\/10.1002\/path.2067","journal-title":"J Pathol"},{"key":"10022_CR14","doi-asserted-by":"publisher","unstructured":"Li G, He X, Zhang L, Ran Q, Wang J, Xiong A, Wu D, Chen F, Sun J, Chang C (2020) Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun:102463. https:\/\/doi.org\/10.1016\/j.jaut.2020.102463","DOI":"10.1016\/j.jaut.2020.102463"},{"key":"10022_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/ejhf.1871","volume":"22","author":"D Tomasoni","year":"2020","unstructured":"Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, Metra M (2020) COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur J Heart Fail 22:957\u2013966. https:\/\/doi.org\/10.1002\/ejhf.1871","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10022_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13034","volume":"21","author":"R Kassir","year":"2020","unstructured":"Kassir R (2020) Risk of COVID-19 for patients with obesity. Obes Rev 21(6):e13034. https:\/\/doi.org\/10.1111\/obr.13034","journal-title":"Obes Rev"},{"issue":"20","key":"10022_CR17","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111(20):2605\u20132610. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.510461","journal-title":"Circulation"},{"issue":"4","key":"10022_CR18","doi-asserted-by":"publisher","first-page":"H1351","DOI":"10.1152\/ajpheart.01186.2004","volume":"289","author":"T Karram","year":"2005","unstructured":"Karram T, Abbasi A, Keidar S, Golomb E, Hochberg I, Winaver J, Hoffman A, Abassi Z (2005) Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol 289(4):H1351\u2013H1358. https:\/\/doi.org\/10.1152\/ajpheart.01186.2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"5","key":"10022_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41569-020-0368-x","volume":"17","author":"JJ Mourad","year":"2020","unstructured":"Mourad JJ, Levy BI (2020) Interaction between RAAS inhibitors and ACE2 in the context of COVID-19. Nat Rev Cardiol 17(5):313. https:\/\/doi.org\/10.1038\/s41569-020-0368-x","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10022_CR20","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1371\/journal.pmed.0020124","volume":"2","author":"JP Ioannidis","year":"2005","unstructured":"Ioannidis JP (2005) Why most published research findings are false. PLoS Med 2(8):e124. https:\/\/doi.org\/10.1371\/journal.pmed.0020124","journal-title":"PLoS Med"},{"issue":"10","key":"10022_CR21","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.mayocp.2013.04.026","volume":"88","author":"V Prasad","year":"2013","unstructured":"Prasad V (2013) Why randomized controlled trials are needed to accept new practices: 2 medical worldviews. Mayo Clin Proc 88(10):1046\u20131050. https:\/\/doi.org\/10.1016\/j.mayocp.2013.04.026","journal-title":"Mayo Clin Proc"},{"key":"10022_CR22","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1161\/CIRCRESAHA.120.317174","volume":"126","author":"R Shah","year":"2020","unstructured":"Shah R, Murthy VL, Koupenova M (2020) ACEing COVID-19: a role for angiotensin axis inhibition in SARS-CoV-2 infection? Circ Res 126:1682\u20131684. https:\/\/doi.org\/10.1161\/CIRCRESAHA.120.317174","journal-title":"Circ Res"},{"issue":"4","key":"10022_CR23","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ahj.2008.11.023","volume":"157","author":"GC Siontis","year":"2009","unstructured":"Siontis GC, Tatsioni A, Katritsis DG, Ioannidis JP (2009) Persistent reservations against contradicted percutaneous coronary intervention indications: citation content analysis. Am Heart J 157(4):695\u2013701. https:\/\/doi.org\/10.1016\/j.ahj.2008.11.023","journal-title":"Am Heart J"},{"issue":"5","key":"10022_CR24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.jacc.2020.05.069","volume":"76","author":"AC Fanaroff","year":"2020","unstructured":"Fanaroff AC, Califf RM, Harrington RA, Granger CB, McMurray JJV, Patel MR, Bhatt DL, Windecker S, Hernandez AF, Gibson CM, Alexander JH, Lopes RD (2020) Randomized trials versus common sense and clinical observation: JACC review topic of the week. J Am Coll Cardiol 76(5):580\u2013589. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.069","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10022_CR25","doi-asserted-by":"publisher","first-page":"e002556","DOI":"10.1136\/bmjopen-2013-002556","volume":"3","author":"A Hartz","year":"2013","unstructured":"Hartz A, He T, Wallace R, Powers J (2013) Comparing hormone therapy effects in two RCTs and two large observational studies that used similar methods for comprehensive data collection and outcome assessment. BMJ Open 3(7):e002556. https:\/\/doi.org\/10.1136\/bmjopen-2013-002556","journal-title":"BMJ Open"},{"issue":"2","key":"10022_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10741-014-9453-8","volume":"20","author":"C Bavishi","year":"2015","unstructured":"Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH (2015) Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev 20(2):193\u2013201. https:\/\/doi.org\/10.1007\/s10741-014-9453-8","journal-title":"Heart Fail Rev"},{"issue":"7023","key":"10022_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","volume":"312","author":"DL Sackett","year":"1996","unstructured":"Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS (1996) Evidence based medicine: what it is and what it isn't. BMJ 312(7023):71\u201372. https:\/\/doi.org\/10.1136\/bmj.312.7023.71","journal-title":"BMJ"},{"issue":"12","key":"10022_CR28","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.rec.2016.11.005","volume":"69","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl Ed) 69(12):1167. https:\/\/doi.org\/10.1016\/j.rec.2016.11.005","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"33","key":"10022_CR29","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, Group ESCSD (2018) 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J 39(33):3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339","journal-title":"Eur Heart J"},{"issue":"2","key":"10022_CR30","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1527-3466.2008.00046.x","volume":"26","author":"A Roca-Cusachs","year":"2008","unstructured":"Roca-Cusachs A, Aracil-Vilar J, Calvo-Gomez C, Vaquer-Perez JV, Laporta-Crespo F, Rojas-Serrano MJ, Guglietta A, Gropper S, Torasemide PRiHCTIG (2008) Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release. Cardiovasc Ther 26(2):91\u2013100. https:\/\/doi.org\/10.1111\/j.1527-3466.2008.00046.x","journal-title":"Cardiovasc Ther"},{"issue":"10","key":"10022_CR31","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1136\/hrt.2005.079764","volume":"92","author":"S Kasama","year":"2006","unstructured":"Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M (2006) Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 92(10):1434\u20131440. https:\/\/doi.org\/10.1136\/hrt.2005.079764","journal-title":"Heart"},{"issue":"4","key":"10022_CR32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E (2020) Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 75(4):422\u2013434. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031","journal-title":"J Am Coll Cardiol"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10022-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-020-10022-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-020-10022-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:20:42Z","timestamp":1630455642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-020-10022-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10022"],"URL":"https:\/\/doi.org\/10.1007\/s10741-020-10022-4","relation":{},"ISSN":["1382-4147","1573-7322"],"issn-type":[{"type":"print","value":"1382-4147"},{"type":"electronic","value":"1573-7322"}],"subject":[],"published":{"date-parts":[[2020,9,1]]},"assertion":[{"value":"27 August 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"F.T. has received research support and honoraria from Amgen, Bayer, Boehringer Ingelheim, Elpen, Lilly, Menarini, Merck, Novartis, Sanofi, Servier, Vianex, and WinMedica.R.C.S. has received research funding from Covia, Amgen, advisory board Medtronic, advisor and steering committee Cardiac Dimensions, steering committee Novartis.A.X. has received honoraria from Novartis.J.B. has received research support from the National Institutes of Health, Patient Centered Outcomes Research Institute and the European Union. He serves as a consultant for Amgen, Array, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharmaceutical, Innolife, Janssen, LinaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sanofi, StealthPeptide, V-Wave Limited, Vifor, and ZS Pharma.H.B. has no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}